Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0.07%
1,101.37
-0.81
-0.07%
—1,102.181,096.241,103.051,090.35——
SIXC
Communications
SIXC
Communications
SIXC
-0.47%
613.35
-2.89
-0.47%
—616.24616.24617.68609.10——
SIXE
Energy
SIXE
Energy
SIXE
+0.77%
1,198.83
+9.11
+0.77%
—1,189.721,194.741,202.791,188.58——
SIXI
Industrials
SIXI
Industrials
SIXI
+1.75%
1,755.95
+30.26
+1.75%
—1,725.691,730.021,762.991,730.02——
SIXM
Financials
SIXM
Financials
SIXM
-0.79%
638.51
-5.11
-0.79%
—643.62643.13643.17632.59——
SIXR
Staples
SIXR
Staples
SIXR
+1.65%
843.52
+13.73
+1.65%
—829.79832.32845.25832.32——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+1.19%
215.95
+2.55
+1.19%
—213.40213.40216.07213.40——
SIXT
Technology
SIXT
Technology
SIXT
-1.48%
3,138.91
-47.01
-1.48%
—3,185.923,160.893,178.723,102.60——
SIXU
Utilities
SIXU
Utilities
SIXU
+2.80%
934.37
+25.43
+2.80%
—908.94912.57934.91912.57——
SIXV
Health care
SIXV
Health care
SIXV
-0.10%
1,477.43
-1.53
-0.10%
—1,478.961,478.171,482.911,466.65——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-1.05%
2,380.19
-25.17
-1.05%
—2,405.362,390.342,402.532,359.18——
GNLX:NASDAQ
Genelux Corp
$2.52
-0.79%
(-0.020) 1D
Apr 23, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GNLX...
Open
$2.58
High
$2.58
Low
$2.48
Mkt. cap
112.91M
Avg. vol.
210.60K
Volume
0.00
52-wk high
$8.54
52-wk low
$2.26
EPS
-$0.86
Beta
0.48
Shares outstanding
44.81M
No. of employees
26
News stories
From sources across the web
Profile
Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity. The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
About Genelux Corp
CEO-
Employees26
Founded2001
HeadquartersWestlake Village, California, United States
SectorBiotechnology
Websitegenelux.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
-
-
-
8.00K
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
4.70M
4.76M
4.74M
5.55M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.12M
3.03M
3.45M
3.87M
Operating expense
7.82M
7.79M
8.19M
9.42M
Total operating expenses
7.82M
7.79M
8.19M
9.42M
Operating income
-7.82M
-7.79M
-8.19M
-9.41M
Other non operating income
140.00K
112.00K
69.00K
37.00K
EBT including unusual items
-7.49M
-7.46M
-7.95M
-9.25M
EBT excluding unusual items
-7.49M
-7.46M
-7.95M
-9.25M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-7.49M
-7.46M
-7.95M
-9.25M
Net profit margin
-
-
-
-115,587.50%
Earnings per share
-0.21
-0.20
-0.21
-0.24
Interest and investment income
184.00K
224.00K
175.00K
128.00K
Interest expense
-
-
-
-
Net interest expenses
184.00K
224.00K
175.00K
128.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-7.76M
-7.73M
-8.13M
-9.35M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer